preprint
A clinical study evaluated the efficacy of the anti-parasitic drug ivermectin combined with standard care for treating mild, moderate, and severe COVID-19 cases, as well as for prevention among healthcare and household contacts. Testing involved 600 participants across six groups, comparing ivermectin regimens against hydroxychloroquine regimens alongside standard care, or personal protective equipment alone for prophylaxis. Patients receiving ivermectin demonstrated marked recovery in laboratory tests, shorter times to negative RT-PCR results, and lower mortality rates compared to those treated with hydroxychloroquine. In severe cases, mortality was reported at two per cent with ivermectin versus twenty per cent with hydroxychloroquine. In prevention cohorts, contact transmission dropped from ten per cent with protective equipment alone to two per cent when supplemented with ivermectin. Overall, the findings suggest ivermectin assists in patient recovery, mortality reduction, and infection prevention.
During health crises involving novel respiratory pathogens, identifying existing medicines that can be repurposed is critical for reducing hospital pressure and mortality. This study suggests that an established anti-parasitic drug could offer therapeutic benefits across varying disease severities and provide prophylactic protection for individuals at high risk of exposure, including healthcare personnel and household members.
The work addresses clinical drug repurposing for healthcare providers managing viral outbreaks. Because ivermectin is an existing pharmaceutical, testing in 600 clinical trial participants suggests applied, tested findings rather than early laboratory research. However, translating these results into approved commercial protocols or clinical guidelines requires regulatory approval and formal adoption by public health authorities and medical practitioners managing infectious diseases.
AI-generated from the published abstract. Always read the original work before citing.
<title>Abstract</title> Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care (azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000) in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts in comparison to the Hydroxychloroquine plus standard treatment. Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; Group I: 100 patients with Mild/Moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care; Group II: 100 patients with mild/moderate COVID-19 infection received hydroxyxholorquine plus standard of care; Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standard of care; Group IV: 100 patients with Severe COVID-19 infection received hydroxyxholorquine plus standard of care. Routine laboratory investigations and RT-PCR were reported before and after initiation of treatment. Group V stick to personal protective equipment (PPE) plus Ivermectin 400mcg / kg to be repeated after one week, and Group VI stick to PPE only and both groups V&VI were followed for two weeks. Results: Patients received ivermectin reported substantial recovery of laboratory investigations; and significant reduction in RT-PCR conversion days. A substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I (mild/moderate cases), (99%, and 0.0%, respectively) and group III (severe cases), (94%, and 2.0%, respectively) versus hydroxychloroquine plus standard care treated groups; group II (mild/moderate cases), (74% and 4%, respectively) and group IV (severe cases) (50% and 20%, respectively). Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group Conclusion: Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only. Early use of Ivermectin is very useful for controlling COVID 19 infections, prophylaxis and improving cytokines storm
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21203/rs.3.rs-100956/v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
